Is Immunotherapy Appropriate Here?Video Categories: 2018 AONN Midyear, Immunotherapy, and Video Library
Dr Morganna Freeman on the challenge of deciding when to treat a patient with immunotherapy.
Dr. Sanjiv Agarwala analyzes anti-PD-1 and anti-PD-L1 therapies in terms what they do and their unique toxicities and response patterns.
Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.